Summary
Many patients suffering from major psychiatric disorders do not respond adequately to monotherapy and require additional drugs. To date, there are no objective guidelines for deciding which combination may be effective, and the choice is based on previous clinical experience and on trial and error. Even when combination drugs are effective, the biochemical mechanisms responsible for the value-added effect are unknown. Understanding the mechanism of such synergism may provide a rational basis for choosing drug combinations and for developing more effective drugs. In schizophrenia, negative symptoms respond poorly to antipsychotics, but may improve when these are augmented with selective serotonin reuptake inhibitors (SSRI). This augmenting effect cannot be explained by summating the pharmacological effects of the individual drugs. We proposed that the study of SSRI augmentation can serve as a window to understanding the biochemical mechanisms of clinically effective drug synergism. In a series of studies we identified unique biochemical effects of the combination, different from each individual drug, and proposed that some of these are involved in mediating the clinical effect. Here we review some of the findings and propose that the mechanism of action involves regionally selective modulation of the GABA system. The evidence indicates that the SSRI antidepressant-antipsychotic combination may be a useful paradigm for studying therapeutically effective synergistic drug interactions in schizophrenia. Although as yet limited in scope, the findings of definable molecular targets for synergistic SSRI-antipsychotic interaction provide new directions to inform future research and provide novel bio-molecular targets for drug development.
Article PDF
Similar content being viewed by others
References
Andreasen NC, Nopoulos P, Schultz S, et al. Positive and negative symptoms of schizophrenia: past, present, and future. Acta Psychiatr Scand Suppl 1994;384:51–59.
Berman RM, Narasimhan M, Chamey DS. Treatment-refractory depression: definitions and characteristics. Depress Anxiety 1997;5:154–164.
Dell’Osso B, Altamura AC, Mundo E, Marazziti D, Hollander E. Diagnosis and treatment of obsessive-compulsive disorder and related disorders. Int J Clin Pract 2007;61:98–104.
Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353: 12: 1209–1223.
Lewis SW, Barnes TRE, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32: 4:715–723.
Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 18:4–11.
Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 2001;7:283–304.
Burton S. Symptom domains of schizophrenia: the role of atypical antipsychotic agents. J Psychopharmacol 2006;20: 6–19.
Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev 2006;3:CD005581.
Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 2000;15:257–261.
Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 1992;31:698–704.
Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 1998;8:208–211.
Chaichan W. Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia. Psychiatry Clin Neurosci 2004;58:364–368.
Hiemke C, Peled A, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 2002;22:502–506.
Lammers CH, Deuschle M, et al. Coadministration of clozapine and fluvoxamine in psychotic patients: clinical experience. Pharmacopsychiatry 1999;32:76–77.
Silver H, Kaplan A, Jahjah N. Fluvoxamine augmentation for clozapine-resistant schizophrenia. Am J Psychiatry 1995;152:1098.
Silver H, Kushnir M, Kaplan A. Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol Psychiatry 1996;40:671–674.
Szegedi A, Anghelescu I, Wiesner J, et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999;32: 148–153.
Silver H, Aharon N, Kaplan A. Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms. Schizophr Bull 2003;29:541–546.
Silver H, Nassar A, Aharon N, Kaplan A. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. Int Clin Psychopharmacol 2003;18:87–92.
Brøsen K. Differences in interactions of SSRIs. Int Clin Psychopharmacol 1998;13 Suppl 5:S45-S47.
Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100:4–22.
Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997;17:102–106.
Weigmann H, Gerek S, Zeisig A, Müller M, Härtter S, Hiemke C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001;23:410–413.
Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18: 2–9.
Avenoso A, Spina E, Campo G, et al. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 1997;35:335–339.
Yasui-Furukori N, Kondo T, Mihara K, Inoue Y, Kaneko S. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia. Psychopharmacology (Berl) 2004;171:223–227.
Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79–91.
de Oliveira IR, Dardennes RM, Amorim ES, et al. Is there a relationship between antipsychotic blood levels and their clinical efficacy? An analysis of studies design and methodology. Fundam Clin Pharmacol 1995;9:488–502.
Volavka J, Cooper TB, Czobor P, et al. High-dose treatment with haloperidol: the effect of dose reduction. J Clin Psychopharmacol 2000;20:252–256.
Poyurovsky M, Kurs R, Weizman A. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder. J Clin Psychiatry 2003;64:611.
Goff DC, Freudenreich O, Evins AE. Augmentation strategies in the treatment of schizophrenia. CNS Spectr 2001;6:904,907–911.
Stoll AL, Haura G. Tranylcypromine plus risperidone for treatment-refractory major depression. J Clin Psychopharmacol 2000;20:495–496.
Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002;42: 165–179.
Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry Suppl 1993;(22):66–78.
Silver H, David D, Kaplan M, et al. An examination of the factor structure of schizophrenic symptoms and comparison of different rating scales. Schizophr Res 1993;10:67–75.
Silver H. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int Clin Psychopharmacol 2003;18:305–313.
Chertkow Y, Weinreb O, Youdim MB, Silver H. Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined [Erratum in: J Neural Trans 2007;114:1455]. J Neural Transm 2007;114: 1443–1454.
Rapoport M, van Reekum R, Mayberg H. The role of the cerebellum in cognition and behavior: a selective review. J Neuropsychiatry Clin Neurosci 2000;12:193–198.
Wong DT, Bymaster FP, Reid LR, Threlkeld PG. Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 1983;32:1287–1293.
Silver H, Youdim MB. MAO-A and MAO-B activities in rat striatum, frontal cortex and liver are unaltered after long-term treatment with fluvoxamine and desipramine. Eur Neuropsychopharmacol 2000;10:125–128.
Baldessarini RJ, Marsh ER, Kula NS. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Res 1992;579:152–156.
Moret C, Briley M. Effect of antidepressant drugs on monoamine synthesis in brain in vivo. Neuropharmacology 1992;31:679–684.
Penttilä J, Kajander J, Aalto S, et al. Effects of fluoxetine on dopamine D2 receptors in the human brain: a positron emission tomography study with [11C]raclopride. Int J Neuropsychopharmacol 2004;7:431–439.
Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000;23: 250–262.
Denys D, Klompmakers AA, Westenberg HG. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl) 2004;176:195–203.
Koch S, Perry KW, Bymaster FP. Brain region and dose effects of an olanzapine-fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 2004;46:232–242.
Ago Y, Nakamura S, Baba A, Matsuda T. Sulphide in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex. Neuropsychopharmacology 2005;30:43–51.
Waldmeier PC. Analysis of the activation of dopamine metabolism by a serotonin uptake inhibitor. Eur J Pharmacol 1979;60:315–322.
Waldmeier PC, Delini-Stula AA. Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 1979;55:363–373.
Chertkow Y, Weinreb O, Youdim MB, Silver H. The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. Int J Neuropsychopharmacol 2006;9: 287–296.
Danovich L, Weinreb O, Youdim MB, Silver H. The molecular mechanism of pharmacodynamic interactions between psychoactive drugs: interactions between antidepressants and antipsychotic drugs. Presented at: Israel Society for Neuroscience Conference Eilat 2007; November 25–27, 2007; Eilat, Israel.
Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000;157:683–94.
Tian J, Chau C, Hales TG, Kaufman DL. GABAA receptors mediate inhibition of T cell responses. J Neuroimmunol 1999;96:21–28.
Avissar S, Roitman G, Schreiber G. Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. Cell Mol Neurobiol 2001;21:799–811.
Ilani T, Ben-Shachar D, Strous RD, et al. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci U S A 2001;98:625–628.
Gladkevich A, Kauffman HF, Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:559–576.
Tang Y, Gilbert DL, Glauser TA, Hershey AD, Sharp FR. Blood gene expression profiling of neurologic diseases: a pilot microarray study. Arch Neurol 2005;62:210–215.
Bowden NA, Weidenhofer J, Scott RJ, et al. Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr Res 2006;82:175–183.
Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 2006;147:126–132.
Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 2001;15:319–339.
Chertkow Y, Weinreb O, Youdim MB, Silver H. Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1356–1362.
Dean B, Hussain T, Hayes W, et al. Changes in serotonin2A and GABAA receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochem 1999;72:1593–1599.
Toyooka K, Watanabe Y, Iritani S, et al. A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. Neurosci Res 2003;46:299–307.
Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 2001;6:293–301.
Bowden NA, Scott RJ, Tooney PA. Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia. Schizophr Res 2007;89:165–168.
Broadbelt K, Ramprasaud A, Jones LB. Evidence of altered neurogranin immunoreactivity in areas 9 and 32 of schizophrenic prefrontal cortex. Schizophr Res 2006;87:6–14.
Reynolds GP, Zhang ZJ, Beasley CL. Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. Brain Res Bull 2001;55:579–584.
Blum BP, Mann JJ. The GABAergic system in schizophrenia. Int J Neuropsychopharmacol 2002;5:159–179.
Hashimoto T, Bazmi HH, Mimics K, Wu Q, Sampson AR, Lewis DA. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry 2008;165: 479–489.
Kalkman HO, Loetscher E. GAD67:the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. J Neural Transm 2003;110:803–812.
Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical γ-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 2000;57:237–245.
Benes FM, Vincent SL, Maric A, Khan Y. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 1996;75:1021–1031.
Deng C, Huang XF. Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia. Exp Brain Res 2006;168:587–590.
Javitt DC. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 2006;19:151–157.
Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008;258:16–27.
Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 2003;97:153–79.
Weinberger DR, Berman KF. Prefrontal function in schizophrenia: confounds and controversies. Philos Trans R Soc Lond B Biol Sci 1996;351:1495–503.
Daskalakis ZJ, Fitzgerald PB, Christensen BK. The role of cortical inhibition in the pathophysiology and treatment of schizophrenia. Brain Res Rev 2007;56:427–42.
Eggan SM, Hashimoto T, Lewis DA. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 2008;65:772–784.
Silver H, Feldman P, Bilker W, Gur RC. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry 2003;160:1809–1816.
Schmitt A, May B, Müller B, et al. Effects of chronic haloperidol and clozapine treatment on AMPA and kainate receptor binding in rat brain. Pharmacopsychiatry 2003;36:292–296.
Zhang HX, Zhao JP, Lv LX, et al. Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia. Neurosci Lett 2008;438:1–5.
Fumagalli F, Frasca A, Racagni G, Riva MA. Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol Pharmacol 2008;73:1484–1490.
Tarazi FI, Baldessarini RJ, Kula NS, Zhang K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2003;306: 1145–1151.
Zink M, Schmitt A, May B, et al. Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr Res 2004;66:151–157.
Zink M, Schmitt A, May B, Müller B, Braus DF, Henn FA. Differential effects of long-term treatment with clozapine or haloperidol on GABA transporter expression. Pharmacopsychiatry 2004;37: 171–174.
Zink M, Schmitt A, May B, et al. Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr Res 2004;66:151–157.
Feng J, Cai X, Zhao J, Yan Z. Serotonin receptors modulate GABAA receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. J Neurosci 2001;21:6502–6511.
Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl) 2006;186:362–372.
Silver H, Knoll G, Isakov V, Goodman C, Finkelstein Y. Blood DHEAS concentrations correlate with cognitive function in chronic schizophrenia patients: a pilot study. J Psychiatr Res 2005;39:569–575.
Strous RD. Dehydroepiandrosterone (DHEA) augmentation in the management of schizophrenia symptomatology. Essent Psychopharmacol 2005;6:141–147.
Tsai GE, Yang P, Chang YC, Chong MY. d-Alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006;59:230–234.
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999;56:29–36.
Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006;60:645–9.
Menzies L, Ooi C, Kamath S, et al. Effects of aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 2007;64:156–167.
Sawaguchi T, Matsumura M, Kubota K. Delayed response deficit in monkeys by locally disturbed prefrontal neuronal activity by bicuculline. Behav Brain Res 1988;31:193–198.
Rao SG, Williams GV, Goldman-Rakic PS. Destruction and creation of spatial tuning by disinhibition: GABAA blockade of prefrontal cortical neurons engaged by working memory. J Neurosci 2000;20:485–494.
Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology 2004;174;1:143–150.
Silver H, Shlomo N, Schwartz M, Hocherman S. Impaired visuomotor function in schizophrenic patients compared with control subjects. J Neuropsychiatry Clin Neurosci 2002;14:72–76.
Silver H, Feldman P. Evidence for sustained attention and working memory in schizophrenia sharing a common mechanism. J Neuropsychiatry Clin Neurosci 2005;17:391–398.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Silver, H., Chertkow, Y., Weinreb, O. et al. Multifunctional pharmacotherapy: What can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?. Neurotherapeutics 6, 86–93 (2009). https://doi.org/10.1016/j.nurt.2008.10.034
Issue Date:
DOI: https://doi.org/10.1016/j.nurt.2008.10.034